Patents by Inventor Ryan Wurz

Ryan Wurz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of KRAS G12C and methods of using the same
    Patent number: 11993597
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: May 28, 2024
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
  • INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME
    Publication number: 20220213101
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: March 10, 2022
    Publication date: July 7, 2022
    Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
  • Inhibitors of KRAS G12C and methods of using the same
    Patent number: 11306087
    Abstract: Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: April 19, 2022
    Assignee: AMGEN INC.
    Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
  • INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME
    Publication number: 20200207766
    Abstract: Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
  • Inhibitors of KRAS G12C and methods of using the same
    Patent number: 10640504
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: May 5, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
  • INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME
    Publication number: 20190077801
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
  • Amides as pim inhibitors
    Patent number: 9394297
    Abstract: The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: July 19, 2016
    Assignee: AMGEN INC.
    Inventors: Victor Cee, Frank Chavez, Jr., Jian J. Chen, Essa Hu Harrington, Bradley Herberich, Claire L. M. Jackson, Brian A. Lanman, Thomas T. Nguyen, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian L. Smith, Nuria A. Tamayo, Andrew Tasker, Hui-Ling Wang, Bin Wu, Ryan Wurz
  • Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use
    Patent number: 9346801
    Abstract: The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: May 24, 2016
    Assignee: Amgen Inc.
    Inventors: Andrew Tasker, Ryan Wurz, Liping H. Pettus, Bradley J. Herberich
  • Azole compounds as PIM inhibitors
    Patent number: 9321756
    Abstract: The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: April 26, 2016
    Assignee: AMGEN INC.
    Inventors: Hui-Ling Wang, Victor J. Cee, Bradley J. Herberich, Claire L. M. Jackson, Brian Alan Lanman, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker
  • AMIDES AS PIM INHIBITORS
    Publication number: 20150329538
    Abstract: The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: February 27, 2013
    Publication date: November 19, 2015
    Applicant: AMGEN INC.
    Inventors: Victor CEE, Frank CHAVEZ, JR., Jian J. CHEN, Essa Hu HARRINGTON, Bradley HERBERICH, Claire L.M. JACKSON, Brian A. LANMAN, Thomas T. NGUYEN, Mark H. NORMAN, Liping H. PETTUS, Anthony B. REED, Adrian L. SMITH, Nuria A. TAMAYO, Andrew TASKER, Hui-Ling WANG, Bin WU, Ryan WURZ
  • Bicyclic pyridazine compounds as Pim inhibitors
    Patent number: 9187486
    Abstract: The invention relates to bicyclic compounds of formulas I and I?, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: November 17, 2015
    Assignee: AMGEN INC.
    Inventors: Derin C. D'amico, Bradley J. Herberich, Claire L. M. Jackson, Liping H. Pettus, Andrew Tasker, Hui-Ling Wang, Bin Wu, Ryan Wurz
  • Bicyclic compounds as Pim inhibitors
    Patent number: 9090593
    Abstract: The invention relates to bicyclic compounds of formula (1?), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: July 28, 2015
    Assignee: AMGEN INC.
    Inventors: Hui-Ling Wang, Kaustav Biswas, Victor J. Cee, Frank Chavez, Jr., Bradley J. Herberich, Claire L. M. Jackson, Brian A. Lanman, Matthew Lee, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Robert M. Rzasa, Shannon Rumfelt, Andrew Tasker, Bin Wu, Ryan Wurz
  • Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use
    Publication number: 20140249131
    Abstract: The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
    Type: Application
    Filed: February 26, 2014
    Publication date: September 4, 2014
    Inventors: Andrew TASKER, Ryan WURZ, Liping H. PETTUS, Bradley J. HERBERICH
  • Bicyclic Pyridazine Compounds as PIM Inhibitors
    Publication number: 20140221344
    Abstract: The invention relates to bicyclic compounds of formulas I and I?, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: April 19, 2012
    Publication date: August 7, 2014
    Inventors: Derin C. D'amico, Bradley J. Herberich, Claire L.M. Jackson, Liping H. Pettus, Andrew Tasker, Hui-Ling Wang, Bin Wu, Ryan Wurz
  • Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
    Patent number: 8772481
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatments of protein kinase mediated diseases, including inflammation and related conditions.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: July 8, 2014
    Assignee: Amgen Inc.
    Inventors: Andrew Tasker, Liping H. Pettus, Ryan Wurz
  • Inhibitors of PI3 kinase and/or mTOR
    Patent number: 8772480
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: July 8, 2014
    Assignee: Amgen Inc.
    Inventors: Kristin L. Andrews, Yunxin Y. Bo, Shon Booker, Victor J. Cee, Noel D'Angelo, Bradley J. Herberich, Fang-Tsao Hong, Claire L. M. Jackson, Brian Alan Lanman, Hongyu Liao, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian Leonard Smith, Seifu Tadesse, Nuria A. Tamayo, Bin Wu, Ryan Wurz, Kevin C. Yang
  • Azole Compounds as PIM Inhibitors
    Publication number: 20140187553
    Abstract: The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 3, 2014
    Applicant: AMGEM INC.
    Inventors: Hui-Ling Wang, Victor J. Cee, Bradley J. Herberich, Claire L.M. Jackson, Brian Alan Lanman, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker
  • BICYCLIC COMPOUNDS AS PIM INHIBITORS
    Publication number: 20140031360
    Abstract: The invention relates to bicyclic compounds of formula (1?), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: December 7, 2011
    Publication date: January 30, 2014
    Applicant: AMGEN INC.
    Inventors: Hui-Ling Wang, Kaustav Biswas, Victor J. Cee, Frank Chavez, JR., Bradley J. Herberich, Claire L.M. Jackson, Brian A. Lanman, Matthew Lee, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Robert M. Rzasa, Shannon Rumfelt, Andrew Tasker, Bin Wu, Ryan Wurz
  • Pyridazino-pyridinone compounds and methods of use
    Patent number: 8455495
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, R1, R2, R3, R4, R5, R6, X and n are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: June 4, 2013
    Assignee: Amgen Inc.
    Inventors: Liping H. Pettus, Andrew Tasker, Hui-Ling Wang, Bin Wu, Ryan Wurz
  • Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
    Patent number: 8435987
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R4, R5, R6 and Z are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: May 7, 2013
    Assignee: Amgen Inc.
    Inventors: Liping H. Pettus, Andrew Tasker, Shimin Xu, Ryan Wurz